RBP2 induces stem-like cancer cells by promoting EMT and is a prognostic marker for renal cell carcinoma.
- Author:
Dahai ZHOU
1
;
Vinodh KANNAPPAN
;
Xiang CHEN
;
Jingqin LI
;
Xuefeng LENG
;
Jinping ZHANG
;
Shiying XUAN
Author Information
- Publication Type:Original Article
- MeSH: Apoptosis; Carcinoma, Renal Cell*; Diagnosis; Epigenomics; Heterografts; Histone Demethylases; Histones; Kidney Neoplasms; Neoplasm Metastasis; Phenotype; Prognosis
- From:Experimental & Molecular Medicine 2016;48(6):e238-
- CountryRepublic of Korea
- Language:English
- Abstract: Renal cell carcinoma (RCC), one of the most common kidney cancers, has a poor prognosis. Epithelial to mesenchymal transition (EMT) is a hallmark of carcinoma invasion and metastasis. Several studies have examined the molecular regulation of EMT, but the relationship between histone demethylases and EMT is little understood. In this study, we investigated the role of retinoblastoma-binding protein-2 (RBP2), a histone demethylase that is highly expressed in RCC and is positively correlated with poor RCC prognosis in the regulation of EMT. We found that ectopic overexpression of RBP2 can induce cancer stem cell-like (CSC) phenotypes through EMT in RCC cells by converting them to a more mesenchymal phenotype. This results in increased resistance to apoptosis, which leads to enhanced tumor growth in xenograft models. Together, our data show that RBP2 is an epigenetic regulator that has an important role in the initiation of CSC phenotypes through EMT, leading to tumor progression. RBP2 is also a novel biomolecule for RCC diagnosis, and prognosis and may be a therapeutic target.
